NCT02319486

CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma

Detailed description

This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .

Conditions

• Retinoblastoma

Interventions

Type	Name	Description
DRUG	carboplatin periocular injection	chemotherapy together with/without 20mg/2ml carboplatin periocular injection
DRUG	CEV chemotherapy	vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2

Timeline

• Start date: 2009-01-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2014-12-18
• Last updated: 2015-03-30
• Results posted: 2015-03-30